PE20220342A1 - Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll - Google Patents

Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll

Info

Publication number
PE20220342A1
PE20220342A1 PE2022000076A PE2022000076A PE20220342A1 PE 20220342 A1 PE20220342 A1 PE 20220342A1 PE 2022000076 A PE2022000076 A PE 2022000076A PE 2022000076 A PE2022000076 A PE 2022000076A PE 20220342 A1 PE20220342 A1 PE 20220342A1
Authority
PE
Peru
Prior art keywords
alkyl
imidazo
ethoxymethyl
diol
amino
Prior art date
Application number
PE2022000076A
Other languages
English (en)
Inventor
Omar Ahmad
Andrew Fensome
Ethan Lawrence Fisher
Erik Alphie Lachapelle
Rayomand J Unwalla
Jun Xiao
Lei Zhang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20220342A1 publication Critical patent/PE20220342A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a compuestos imidazo-piridinilo de formula (I), R1 y R2 son C1-3 alquilo; o R1 y R2 se unen para formar un anillo carbociclico de 5 a 7 miembros, en donde dicho anillo carbociclico puede ser saturado o insaturado; R3 es -CH2-CR2(CH2-OH)-CH2-O-R6; R4 es C1-6 alquilo, o (CH2)nO(CH2)mCH3, en donde el C1-6 alquilo o cualquier carbono del grupo (CH2)nO(CH2)mCH3 se sustituye con 0 a 3 halogenos, como lo permita la valencia; R5 es C1-3 alquilo, u OC1-3 alquilo, en donde C1-3 alquilo se sustituye con 0 a 3 F; R6 es H, o C1-3 alquilo, en donde C1-3 alquilo se sustituye con 0 a 3 F; m es 0 a 2; y n es 1 a 3. Son compuestos preferidos: 2-((4-amino-2-(etoximetil)-6,7-dimetil-1H-imidazo[4,5-c]piridin-1-il)metil)-2- metilpropan-1,3-diol; 2-((4-amino-2-(etoximetil)-1H-imidazo[4,5-c]quinolin-1-il)metil)-2- metilpropan-1,3-diol; 2-((4-amino-2-(etoximetil)-7,8-dihidrociclopenta[b]imidazo[4,5-d]piridin1(6H)-il)metil)-2-metilpropan-1,3-diol; entre otros. Dichos compuestos son utiles para el tratamiento de crecimiento celular anormal, que incluye cancer.
PE2022000076A 2019-07-17 2020-07-14 Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll PE20220342A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875465P 2019-07-17 2019-07-17
US202062961288P 2020-01-15 2020-01-15
PCT/IB2020/056605 WO2021009676A1 (en) 2019-07-17 2020-07-14 Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits

Publications (1)

Publication Number Publication Date
PE20220342A1 true PE20220342A1 (es) 2022-03-14

Family

ID=71728839

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000076A PE20220342A1 (es) 2019-07-17 2020-07-14 Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll

Country Status (20)

Country Link
US (2) US11339159B2 (es)
EP (1) EP3999507A1 (es)
JP (1) JP7137733B2 (es)
KR (1) KR20220034862A (es)
CN (1) CN114364677A (es)
AU (1) AU2020315210B2 (es)
BR (1) BR112022000341A2 (es)
CA (1) CA3147266C (es)
CL (1) CL2022000032A1 (es)
CO (1) CO2022000259A2 (es)
CR (1) CR20220018A (es)
CU (1) CU20220003A7 (es)
EC (1) ECSP22003665A (es)
IL (1) IL289877A (es)
MX (1) MX2022000656A (es)
PE (1) PE20220342A1 (es)
TW (1) TWI755788B (es)
UY (1) UY38786A (es)
WO (1) WO2021009676A1 (es)
ZA (1) ZA202201330B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
US11339159B2 (en) * 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2022153157A1 (en) 2021-01-13 2022-07-21 Pfizer Inc. A crystalline form of 2-((4-amino-2-(ethoxymethyl)-6,7-dimethyl-1 h-imidazo[4,5-c]pyridin-1-yl)methyl)-2-methylpropane-1,3-diol free base
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
ES2149276T3 (es) 1993-07-15 2000-11-01 Minnesota Mining & Mfg Imidazo(4,5-c)piridin-4-aminas.
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CN1897948A (zh) 2003-10-03 2007-01-17 3M创新有限公司 烷氧基取代的咪唑并喹啉
WO2006009832A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8846710B2 (en) * 2005-02-23 2014-09-30 3M Innovative Properties Company Method of preferentially inducing the biosynthesis of interferon
CA2686163A1 (en) 2007-05-08 2008-11-13 Astrazenca Ab Imidazoquinolines with immuno-modulating properties
CN101918447B (zh) 2007-12-14 2014-06-11 布里斯托尔-米尔斯·斯奎布公司 人ox40受体的结合分子
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
PE20190515A1 (es) 2011-11-17 2019-04-10 Pfizer Peptidos modificados de auristatina y conjugados anticuerpo-farmaco de los mismos
PT3134402T (pt) * 2014-04-22 2020-07-02 Hoffmann La Roche Compostos de 4-amino-imidazoquinolina
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
HUE053704T2 (hu) * 2014-12-08 2021-07-28 Hoffmann La Roche 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére
KR102405099B1 (ko) 2015-04-13 2022-06-07 화이자 인코포레이티드 치료 항체 및 그의 용도
US10351582B2 (en) 2015-12-14 2019-07-16 Glaxosmithkline Biologicals, S.A. Pegylated imidazoquinolines
CN109071514B (zh) 2016-04-07 2021-07-06 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
BR112018070602A2 (pt) 2016-04-07 2019-02-05 Glaxosmithkline Ip Dev Ltd composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
US10533007B2 (en) * 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
US10562178B2 (en) 2016-11-16 2020-02-18 Wink Robotics Machine for beauty salon
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CA3065301A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018220584A1 (en) 2017-06-02 2018-12-06 Pfizer Inc. Antibodies specific for flt3 and their uses
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
US11339159B2 (en) * 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists

Also Published As

Publication number Publication date
US11976064B2 (en) 2024-05-07
KR20220034862A (ko) 2022-03-18
US20220274986A1 (en) 2022-09-01
WO2021009676A8 (en) 2022-03-03
JP2022534125A (ja) 2022-07-27
AU2020315210A1 (en) 2022-02-03
UY38786A (es) 2021-02-26
MX2022000656A (es) 2022-02-16
CA3147266A1 (en) 2021-01-21
BR112022000341A2 (pt) 2022-04-12
CU20220003A7 (es) 2022-08-09
TWI755788B (zh) 2022-02-21
CL2022000032A1 (es) 2022-09-02
US11339159B2 (en) 2022-05-24
EP3999507A1 (en) 2022-05-25
TW202116770A (zh) 2021-05-01
CA3147266C (en) 2023-09-12
IL289877A (en) 2022-03-01
CO2022000259A2 (es) 2022-01-17
AU2020315210B2 (en) 2023-01-12
CN114364677A (zh) 2022-04-15
CR20220018A (es) 2022-02-08
ECSP22003665A (es) 2022-02-25
ZA202201330B (en) 2022-10-26
WO2021009676A1 (en) 2021-01-21
US20210017172A1 (en) 2021-01-21
JP7137733B2 (ja) 2022-09-14

Similar Documents

Publication Publication Date Title
PE20220342A1 (es) Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll
PE20170403A1 (es) COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER
PE20240584A1 (es) Agonistas del receptor de glp-1 y usos de los mismos
PE20120172A1 (es) Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide
ECSP15029636A (es) Nuevos compuestos bicíclicos y su uso como agentes antibacterianos e inhibidores de beta-lactamasa
PE20160588A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
CL2021002296A1 (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
PE20091485A1 (es) DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS
CO6300941A2 (es) Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7
PE20210160A1 (es) Moduladores de nlrp3
ECSP10010349A (es) Derivados de ftalazinona
UY27834A1 (es) Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos.
AR083358A1 (es) Compuestos de furo[3,2-d]pirimidina
PE20130376A1 (es) [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
PE20030477A1 (es) ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20160589A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a
PE20161552A1 (es) Compuestos de dihidroisoquinolinona sustituida
AR076360A1 (es) Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
PE20140571A1 (es) Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
PE20110122A1 (es) COMPUESTOS DERIVADOS DE 9H-PIRROLO[2,3-b:5,4-c]DIPIRIDIN-6-(PIRIDIN-3-IL) COMO INHIBIDORES DE LAS CINASA Pim
PE20121556A1 (es) 3,6-diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina
PE20211868A1 (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cancer
CO6410299A2 (es) Derivados de triazolo [4,3-b] pridazina y sus usos para el cáncer de próstata